Healthcare
Vitrolife AB (publ)(VTRLY)
Live Price
Offline$10.70
+0.00% today
1Y Change
-24.76%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $14.67B
- Revenue Growth
- -10.4%
- EPS Growth
- -1017.9%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vitrolife AB (publ) (VTRLY) is a Healthcare stock with a market cap of $14.67B and listed on OTC. The stock last traded around $10.70 and down 24.8% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -10.4%, EPS growth of -1017.9%, a dividend yield of 0.0%. What stands out right now is revenue -10.4%, EPS -1017.9%, free cash flow -62.2% with operating margin 18.0% and ROIC 5.7%. Valuation sits in the middle of the pack at price/sales 4.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VTRLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-10.4% vs +7.6% peer median
Operating Margin
Near sector median
+18.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 22, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -10.4% and EPS is at -1017.9%, with operating margin around 18.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 22, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Jan 29, 2026 | โ | +0.0% | +0.0% | -37.9% |
2025 Jul 17, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTRLY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VTRLY Max Drawdown
-48.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VTRLY and SPY.
Company Overview
Vitrolife AB (publ)
Other OTC
Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
- Leadership
- Bronwyn Brophy O'Connor
- IPO Date
- Aug 10, 2016
- Employees
- 1.1k
- Street Address
- Gustaf Werners gata 2
- Mailing
- Gothenburg, 421 32
- Region
- Gothenburg, SE
- Reporting Currency
- USD
- Investor Line
- 46 3 17 21 80 00
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.3
- Price/Book
- 1.8
Growth
- Revenue
- -10.4%
- EPS
- -1017.9%
- Free Cash Flow
- -62.2%
Profitability
- Gross Margin
- 51.4%
- Operating Margin
- 18.0%
- Net Margin
- -147.2%
- ROE
- -47.1%
- ROIC
- 5.7%
Balance Sheet
- Debt/Equity
- 0.20
- Current Ratio
- 3.68
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.